BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

Valneva gets $130M up front in Lyme disease vaccine deal  Pfizer Inc. (NYSE:PFE) will collaborate with Valneva SE (Euronext:VLA) to develop VLA15, the biotech’s vaccine candidate for Lyme disease. In a deal announced Thursday, Valneva...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 2, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
BC Extra | Nov 1, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Sep 21, 2018
Company News

Siga signs BARDA contract for smallpox drug worth up to $629M

Siga Technologies Inc. (NASDAQ:SIGA) signed a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA) to deliver oral and IV formulations of its TPOXX tecovirimat drug to the U.S. Strategic National Stockpile. In July,...
BC Week In Review | Jul 20, 2018
Clinical News

Siga gets Priority Review voucher for first approved smallpox drug

Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga gained $1.11 (18%) to $7.35 on July...
BC Extra | Jul 13, 2018
Company News

Siga gets Priority Review voucher for first approved smallpox drug

Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga gained $1.11 (18%) to $7.35 on Friday...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | May 4, 2018
Clinical News

FDA panel backs Siga's antiviral for smallpox

Siga Technologies Inc. (NASDAQ:SIGA) said FDA's Antimicrobial Drugs Advisory Committee voted 17-0 on May 1 that the benefit-risk profile of oral TPOXX tecovirimat (oral ST-246) supports its use to treat smallpox infection. The candidate's PDUFA...
Items per page:
1 - 10 of 192
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

Valneva gets $130M up front in Lyme disease vaccine deal  Pfizer Inc. (NYSE:PFE) will collaborate with Valneva SE (Euronext:VLA) to develop VLA15, the biotech’s vaccine candidate for Lyme disease. In a deal announced Thursday, Valneva...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 2, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
BC Extra | Nov 1, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Sep 21, 2018
Company News

Siga signs BARDA contract for smallpox drug worth up to $629M

Siga Technologies Inc. (NASDAQ:SIGA) signed a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA) to deliver oral and IV formulations of its TPOXX tecovirimat drug to the U.S. Strategic National Stockpile. In July,...
BC Week In Review | Jul 20, 2018
Clinical News

Siga gets Priority Review voucher for first approved smallpox drug

Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga gained $1.11 (18%) to $7.35 on July...
BC Extra | Jul 13, 2018
Company News

Siga gets Priority Review voucher for first approved smallpox drug

Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga gained $1.11 (18%) to $7.35 on Friday...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | May 4, 2018
Clinical News

FDA panel backs Siga's antiviral for smallpox

Siga Technologies Inc. (NASDAQ:SIGA) said FDA's Antimicrobial Drugs Advisory Committee voted 17-0 on May 1 that the benefit-risk profile of oral TPOXX tecovirimat (oral ST-246) supports its use to treat smallpox infection. The candidate's PDUFA...
Items per page:
1 - 10 of 192